{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:42:58Z","timestamp":1777934578088,"version":"3.51.4"},"reference-count":8,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2023,7]]},"abstract":"\n Introduction<\/jats:title>\n Cyclin-dependent kinase (CDK) 4\/6 inhibitors have shown a different adverse effect. In this case, persistent grade 3 hepatoxicity was observed after ribociclib. Therefore, ribociclib therapy was stopped, and then palbociclib was introduced. Transaminase levels returned to normal by switching to palbociclib therapy.<\/jats:p>\n <\/jats:sec>\n \n Case report<\/jats:title>\n 71-year-old postmenopausal female patient with luminal subtypes of metastatic breast cancer treated with ribociclib.<\/jats:p>\n <\/jats:sec>\n \n Management & outcome<\/jats:title>\n Grade 3 hepatotoxicity secondary to ribociclib developed. She was successfully treated with palbociclib 125\u2005mg.<\/jats:p>\n <\/jats:sec>\n \n Discussion<\/jats:title>\n In our case, palbociclib was started with a full dose, to increase treatment success. Starting with a 125\u2005mg dose was not cause any toxicity. Nevertheless, laboratory follow-up is required in terms of neutropenia and increased transaminases.<\/jats:p>\n <\/jats:sec>","DOI":"10.1177\/10781552231154009","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T03:18:30Z","timestamp":1675999110000},"page":"1275-1277","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":10,"title":["Ribociclib-induced hepatotoxicity"],"prefix":"10.1177","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0583-0295","authenticated-orcid":false,"given":"Muhammed Muhiddin","family":"Er","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Necmettin Erbakan University School of Medicine, Konya, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murat","family":"Araz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Necmettin Erbakan University School of Medicine, Konya, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6970-4733","authenticated-orcid":false,"given":"Engin","family":"Hendem","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Necmettin Erbakan University School of Medicine, Konya, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2597-5931","authenticated-orcid":false,"given":"Melek Karakurt","family":"Ery\u0131lmaz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Necmettin Erbakan University School of Medicine, Konya, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2335-3354","authenticated-orcid":false,"given":"Mehmet","family":"Arta\u00e7","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Necmettin Erbakan University School of Medicine, Konya, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,2,10]]},"reference":[{"key":"bibr1-10781552231154009","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy192"},{"key":"bibr2-10781552231154009","doi-asserted-by":"publisher","DOI":"10.1111\/tbj.13532"},{"key":"bibr3-10781552231154009","first-page":"425","volume":"17","author":"Cristofanilli M","year":"2016","journal-title":"LancetOncol"},{"key":"bibr4-10781552231154009","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.9909"},{"key":"bibr5-10781552231154009","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01235"},{"key":"bibr6-10781552231154009","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609709"},{"key":"bibr7-10781552231154009","first-page":"1382","volume":"59","author":"Kessler L E","year":"2020","journal-title":"ActaOncol"},{"key":"bibr8-10781552231154009","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000845"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552231154009","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552231154009","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552231154009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:27:56Z","timestamp":1777688876000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552231154009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,10]]},"references-count":8,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.1177\/10781552231154009"],"URL":"https:\/\/doi.org\/10.1177\/10781552231154009","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,10]]}}}